Diagnostics of Chronic Endometritis in Infertility
Evaluation of the Congruity of Methods Used in the Diagnostics of Chronic Endometritis in the Course of Infertility and the Effectiveness of Antibiotic Therapy in the Context of Remission of Symptoms and Obstetric Results
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The objectives are as follows:
- Estimation of the diagnostic congruity of hysteroscopic, histopathological and microbiological diagnoses of CE
- Estimation of the effectiveness of empirical antibiotic therapy in the treatment of CE, confirmed by normalization of the hysteroscopic appearance of the uterine cavity, normalization of histopathological results of endometrial biopsies and decrease in plasma cell count/1 high power field (HPF)
- Estimation of the percentage of clinical pregnancies achieved in women subjected to empiric antibiotic therapy for CE vs. in women without treatment. The study group will consist of women of childbearing age subjected to office hysteroscopy due to intrauterine pathologies, AUB, and idiopathic infertility. The prerequisite for hysteroscopy is a normal cervical cytology result, a negative blood pregnancy test, a normal vaginal biocenosis and the first phase of the cycle. During hysteroscopy, the following will be performed: visual inspection of the uterine cavity in search of focal lesions and features of the endometrium suggestive of CE, such as: focal or diffuse hyperemia, micropolyps, stromal edema, then collection of washings from the uterine cavity for microbiological examination (aerobic and anaerobic culture, PCR for Chlamydia, culture for Mycoplasma, Ureaplsma) and excision of the focal lesion or endometrial biopsy. The extracted tissue material will be subjected to standard histopathological examination with hematoxylin and eosin staining. Additional immunohistochemical staining with Monoclonal Mouse Anti-Human CD138 antibodies will be used to detect plasmocytes. The cut-off point for the number of CE-defining plasmocytes will be determined by the Receiver Operating Characteristic (ROC) curve. Women diagnosed with CE will be assigned to 2 arms: 1) ofloxacin 2x200 mg orally for 10 days + metronidazole 1x500 mg vaginally for 10 days, 2) control arm (no treatment). In the third cycle after the primary hysteroscopy, women will undergo a follow-up office hysteroscopy for a visual assessment of the uterine cavity and a follow-up endometrial biopsy. The percentage of women with improvement in the clinical appearance of the uterine cavity, normalization of histopathology and persistent CE in both arms will be determined. Data will be obtained on the results of infertility treatment (obtaining a clinical pregnancy) within 24 months of the procedure or completion of antibiotic therapy.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Malopolska
-
Krakow, Malopolska, Poland, 31-501
- Jagiellonian University Medical College, Department of Gynecology and Obstetrics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 18-45 years
- lack of previous diagnosis and treatment due to suspected pathology of the uterine cavity
- lack of active infection of the reproductive tract
Exclusion Criteria:
- pelvic surgery performed within 6 months preceding the hysteroscopy
- confirmed pelvic endometriosis
- antibiotic or probiotic treatment within 3 months preceding the hysteroscopy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Antibiotic therapy
Women diagnosed with CE undergoing empirical antibiotic therapy
|
Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
|
|
No Intervention: Control
Women diagnosed with CE not subjected to empirical antibiotic therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determination of the cut-off point of the number of plasma cells/1 HPF corresponding to histological CE
Time Frame: 3 months
|
Diagnostic compatibility assessment of immunohistochemistry and histopathology will be performed to estimate the cut-off point for the number of plasma cells defining CE using the ROC (Receiver Operating Characteristic) curve
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of the reliability of polyp visualization in diagnosing CE
Time Frame: 3 months
|
The percentage of women with CE and a hysteroscopy-visible endometrial polyp and without a polyp will be calculated and compared
|
3 months
|
|
Assessment of the reliability of the visualization of focal endometrial hyperemia in the diagnosis of CE
Time Frame: 3 months
|
The percentage of women with CE and hysteroscopy-visible focal hyperemia and without hyperaemia will be calculated and compared
|
3 months
|
|
Assesment of the reliability of the visualization of diffuse endometrial hyperemia in the diagnosis of CE
Time Frame: 3 months
|
The percentage of women with CE and hysteroscopy-visible diffuse hyperaemia and without hyperaemia will be calculated and compared
|
3 months
|
|
Assessment of the reliability of the visualization of endometrial micropolyps in the diagnosis of CE
Time Frame: 3 months
|
The percentage of women with CE and hysteroscopy-visible micropolyps and without micropolyps will be calculated and compared
|
3 months
|
|
Assessment of the reliability of the visualization of endometrial edema in the diagnosis of CE
Time Frame: 3 months
|
The proportion of women with CE and hysteroscopy-visible endometrial edema and without endometrial edema will be calculated and compared
|
3 months
|
|
Evaluation of the effectiveness of antibiotic therapy in the context of reducing the number of plasma cells/1 mm2
Time Frame: 3 months
|
The number of plasma cells/1 mm2 will be calculated and compared among women who received antibiotic therapy in the course of CE and untreated women
|
3 months
|
|
Evaluation of the effectiveness of antibiotic therapy in the context of visual normalization of the uterine cavity in follow-up hysteroscopy
Time Frame: 3 months
|
The percentage of women with persistent hysteroscopic CE symptoms: visualization of focal hyperemia or diffuse hyperemia or endometrial micropolyps or endometrial edema in follow-up hysteroscopy will be assessed and compared among women who received antibiotic therapy in the course of CE and untreated women
|
3 months
|
|
Evaluation of the effectiveness of antibiotic therapy in the context of normalization of histopathological results of a control endometrial biopsy
Time Frame: 3 months
|
The percentage of women with persistent histopathological CE symptoms: presence of plasma cells and/or other inflammatory cells (lymphocytes or neutrophilic granulocytes or histiocytes/macrophages or eosinophilic granulocytes) destructing the endometrial tubuli among women who received antibiotic therapy in the course of CE and untreated women will be evaluated and compared in follow-up hysteroscopic endometrial biopsy
|
3 months
|
|
Evaluation of the effectiveness of antibiotic therapy in the treatment of CE - dependent infertility
Time Frame: 24 months
|
Pregnancy rates will be assessed and compared among women who received antibiotics for CE and untreated women
|
24 months
|
|
Evaluation of the effectiveness of antibiotic therapy in the treatment of CE - dependent abnormal uterine bleeding
Time Frame: 24 months
|
The rates of persistence of abnormal uterine bleeding will be assessed and compared in women who received antibiotics for CE and in untreated women.
|
24 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the frequency of isolation of a specific pathogen in the course of CE
Time Frame: 3 months
|
The co-occurrence of a specific pathogen in CE and its type will be assessed using conventional microbiological methods
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Robert Jach, Prof., PhD, Jagiellonian University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Hemorrhage
- Adnexal Diseases
- Pelvic Inflammatory Disease
- Uterine Hemorrhage
- Infertility
- Endometritis
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Topoisomerase Inhibitors
- Topoisomerase II Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Metronidazole
- Ofloxacin
Other Study ID Numbers
Other Study ID Numbers
- 1072.6120.322.2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.